Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22236839 | 0.92 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2KDM4ETHRB | |
| SCHEMBL22236871 | 0.88 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2KDM4ETHRB | |
| SCHEMBL22236838 | 0.85 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2KDM4ETHRB | |
| SCHEMBL18133285 | 0.82 | SSTR3 (0.34) | SSTR3 | |
| SCHEMBL15929407 | 0.81 | LMNA (0.35) | LMNAALDH1A1CNR2MAPTRECQL | |
| SCHEMBL18133284 | 0.81 | SSTR3 (0.38) | MEN1KMT2ASMN1; SMN2KDM4ETHRB | |
| SCHEMBL15929419 | 0.79 | MAPT (0.41) | MEN1KMT2ASMN1; SMN2KDM4ETDP1 | |
| SCHEMBL15929412 | 0.78 | DNM1 (0.32) | LMNAALDH1A1CNR2MAPTRECQL | |
| SCHEMBL15929409 | 0.77 | MGLL (0.48) | TDP1LMNAALDH1A1MAPTRECQL | |
| SCHEMBL15929426 | 0.76 | GRIN2D (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542267-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2023-01-03 | — | — | US | disclosed |
| US-11535623-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2022-12-27 | — | — | US | disclosed |
| US-20200308183-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308183-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | MEN1 61/4885KMT2A 3564/4885SMN1; SMN2 3013/4885 |
| US-11542267-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | MEN1 61/4885KMT2A 3564/4885SMN1; SMN2 3013/4885 |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | MEN1 61/4885KMT2A 3564/4885SMN1; SMN2 3013/4885 |
| US-11535623-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | MEN1 61/4885KMT2A 3564/4885SMN1; SMN2 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.